Bimmugen [Recombinant adsorbed hepatitis B vaccine (yeast-derived)] is Kaketsuken’s monovalent vaccine that protects infants against acute and chronic infections caused by all known strains of HBV. In 1988, Bimmugen became the first HBV vaccine available in Japan. The antigen contained in Bimmugen, purified recombinant HBsAg, is obtained by culturing S. cerevisiae cells that have been genetically engineered to express the viral protein. All dosages and formulations of Bimmugen are administered by intramuscular injection.
Complete report is available @ http://www.rnrmarketresearch.com/bimmugen-prophylactic-hepatitis-b-virus-vaccines-forecast-and-market-analysis-to-2022-market-report.html . Read more on “Bimmugen (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022” report below.
